Vaccine to Fight New Bird Flu Strain Could Be Elusive

April 11, 2013, 8:09 p.m. ET

Vaccine to Fight New Bird Flu Strain Could Be Elusive

By BETSY MCKAY

Developing a vaccine to protect people from the new H7N9 flu virus that recently emerged in eastern China could prove to be especially difficult, flu experts from the U.S. Centers for Disease Control and Prevention reported in a paper Thursday.

As with many new flu viruses, it isn’t clear yet whether the new flu will create only “sporadic human infections from an animal source” or whether it will “signal the start of an influenza pandemic,” CDC flu scientists Timothy Uyeki and Nancy Cox wrote in an article published online in the New England Journal of Medicine.

In addition, they wrote, “there are many challenges to making H7N9 vaccines available.” Vaccines against H7 avian flu viruses that have already been studied haven’t produced a strong immune response in humans, they wrote. And like any new vaccine, it would likely take many months to produce and distribute, they wrote, adding “extensive efforts” to develop vaccines are under way.They called for intensified surveillance in both people and animals to determine whether the new virus is transmitting from one person to another and to answer other questions. So far, scientists say no evidence has been found of person-to-person transmission of the disease.

The number of patients in China confirmed with H7N9 flu had climbed to 38 as of Thursday, including 10 deaths, according to the World Health Organization. More than 760 people who were in close contact with those confirmed cases are being closely monitored, the Geneva agency said.

In another article published Thursday, also in the New England Journal of Medicine, a team of Chinese scientists said the new H7N9 virus was likely transmitted to people directly from birds rather than mammals. Chinese officials destroyed flocks of poultry late last week, after learning that some patients had had contact with birds before becoming ill.

The scientists hypothesized that the virus formed, or “reassorted,” from three different avian viruses. The new virus contains genes resembling those found in viruses circulating in wild birds, ducks, and a brambling in Beijing, they wrote.

“Currently, there are no data to suggest that this reassortment occurred in a mammalian host,” they wrote.

The scientists drew their conclusions from studying virus samples from the first three H7N9 patients. Those patients, ages 87, 27, and 35, all died. All three had underlying medical conditions, including hypertension, hepatitis B, and chronic obstructive pulmonary disease.

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment